A single dose of an experimental drug dramatically reduced levels of a deadly form of cholesterol, often thought to be ...

The Eli Lilly drug caused a major drop in the blood levels of Lp(a), but further research is needed to show that it will ...

The experimental drug lepodisiran, developed by Eli Lilly, significantly lowered levels of the genetically inherited heart ...

CHICAGO — Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more ...

Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated ...

Heart disease remains the leading cause of death in America, and while many are aware of the impact of lifestyle choices on ...

Eli Lilly's experimental drug, lepodisiran, showcased remarkable efficacy in reducing lipoprotein(a) levels, a heart disease risk factor, by up to 95% in a midstage trial. The innovative treatment ...

Awareness Day, and it’s a great opportunity to discuss lipids and howlipoprotein (a) might differ from your general understanding of how cholesterol works in our bodies.

Merck joins a growing list of companies targeting lipoprotein(a), high levels of which are associated with an elevated risk ...

A new study published in the Journal of American Medical Association showed that the innovative small interfering RNA (siRNA) medication olpasiran (Amgen) can effectively reduce lipoprotein(a) ...

Eli Lilly (LLY) and Company announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA, siRNA, therapy ...

This popular dish is loaded with a special variety of fibre that assists in eliminating 'bad' cholesterol from the body.